SUBSCRIBE
SUBSCRIBE
News   Drug Development

Cardiome Pharma Corp. Says Heart Drug Program Delayed, Shares Fall

August 11, 2010 | 
1 min read
Aug 11 (Reuters) - Canada's Cardiome Pharma Corp (COM.TO) said the development of its key drug to treat irregular heart beats will be delayed, sending its shares down as much as 18 percent on Wednesday morning.
Clinical research Phase II Phase III FDA Approvals
MORE ON THIS TOPIC
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
June 26, 2025
 · 
4 min read
 · 
Annalee Armstrong
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
FDA
FDA Names Psychedelic Proponent as CDER Deputy Director, Top Spot Remains Open
June 25, 2025
 · 
2 min read
 · 
Tristan Manalac
Artwork magazine collage picture of serious confident lady looking big enlargement glass isolated drawing background.
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
 · 
3 min read
 · 
Tristan Manalac